Indivior /INDV

0.38%
-
1D1W1MYTD1YMAX

About Indivior

Indivior PLC is a pharmaceutical company. The Company develops medicines to treat addiction and serious mental illnesses. The Company focuses on building a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its Sublocade, Subutex, and Suboxone are used for the treatment of opioid use disorder (OUD). Perseris is used for the treatment of Schizophrenia. The Company's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine Sublingual and Naloxone Film, and Buprenorphine and Naloxone Sublingual Tablet. Its pipeline also includes the Orexin-1 Receptor Antagonist Program.

Ticker

INDV

Sector

Healthcare

Trading on

LSE

Industry

Biotechnology & Drugs

CEO

Mark Crossley

Employees

1,051

Headquarters

Slough, United Kingdom

Indivior Metrics

BasicAdvanced
£2.67B
Market cap
-
P/E ratio
-£0.05
EPS
-0.23
Beta
-
Dividend rate
£2.67B
-0.2263
£24.13
£14.01
498.25K
0.968
0.859
0.11%
7.84%
0.29%
2.439
26.36%
111.79%
19.1%

What the Analysts think about Indivior

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
57.67% upside
High £25.14
Low £24.04
£15.71
Current price
£24.77
Average price target

Indivior Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
18.43% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$293M
8.12%
Net income
$54M
-140%
Profit margin
18.43%
-137%

Indivior Earnings Performance

No data availble
Quarterly data is not available. You can look at the annual data instead.

Earnings per share (EPS)

Company profitability
-
QuarterlyAnnual
Actual
Expected
Surprise
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by ICE Data Services and LSEG. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Indivior stock?

Indivior (INDV) has a market cap of £2.67B as of April 15, 2024.

What is the P/E ratio for Indivior stock?

The price to earnings (P/E) ratio for Indivior (INDV) stock is 0 as of April 15, 2024.

Does Indivior stock pay dividends?

No, Indivior (INDV) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Indivior dividend payment date?

Indivior (INDV) stock does not pay dividends to its shareholders.

What is the beta indicator for Indivior ?

Indivior (INDV) has a beta rating of -0.23. This means that it has an inverse relation to market volatility.

What is the Indivior stock price target?

The target price for Indivior (INDV) stock is £24.77, which is 57.67% above the current price of £15.71. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Indivior  stock

Buy or sell Indivior stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing